Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 6, 2005, Pages 1547-1551

  Usui, Shinya ^a   Suzuki, Takayoshi ^a   Hattori, Yoshifumi ^a   Etoh, Kazuma ^a   Fujieda, Hiroki ^a   Nishizuka, Makoto ^a   Imagawa, Masayoshi ^a   Nakagawa, Hidehiko ^a   Kohda, Kohfuku ^a,b   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

15d PGJ2; Agonist; Insulin sensitizer; PPAR ligand

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; RAT; STRUCTURE ANALYSIS;

EID: 20044388313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.074     Document Type: Article

References (22)

1. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke J. Med. Chem. 43 2000 527
2. T.M. Willson, J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, and J.M. Lehmann J. Med. Chem. 39 1996 665
3. S. Kersten, B. Desvergne, and W. Wahli Nature 405 2000 421
4. I. Bogacka, H. Xie, G.A. Bray, and S.R. Smith Diabetes Care 27 2004 1660
5. B.C.C. Cantello, M.A. Cawthorone, G.P. Cottam, P.T. Duff, D. Haigh, R.M. Hindley, C.A. Lister, S.A. Smith, and P.L. Thurlby J. Med. Chem. 37 1994 3977
6. Y. Momose, K. Meguro, H. Ikeda, C. Hatanaka, S. Oi, and T. Sohda Chem. Pharm. Bull. 39 1991 1440
7. Liver damage warning for Troglitazone Scrip. 1997, 2282, 21
8. Patel, J.; Miller, E.; Hu, J.; Granett, J. Diabetes 1997, 46 (Suppl. 1), Abstr. 0578
9. B.R. Henke, S.G. Blanchard, M.F. Brackeen, K.K. Brown, J.E. Cobb, J.L. Collins, W.W. Harrington, M.A. Hashim, E.A. Hull-Ryde, I. Kaldor, S.A. Kliewer, D.H. Lake, L.M. Leesenitzer, J.M. Lehmann, J.M. Lenhard, L.A. Orband-Miller, J.F. Miller, R.A. Mook, S.A. Noble, W. Oliver, D.J. Parks, K.D. Plunket, J.R. Szewczyk, and T.M. Willson J. Med. Chem. 41 1998 5020
10. A.P. Krapcho, M.J. Maresch, and J. Lunn Synth. Commun. 23 1993 2443
11. For a review see: O. Mitsunobu Synthesis 1981 1
12. S. Wagaw, and S.L. Buchwald J. Org. Chem. 61 1996 7240
13. T. Kanayama, S. Mamiya, T. Nishihara, and J. Nishikawa J. Biochem. 133 2003 791
14. P.J. Rybczynski, R.E. Zeck, J. Dudash Jr., D.W. Combs, T.P. Burris, M. Yang, M.C. Osborne, X. Chen, and K.T. Demarest J. Med. Chem. 47 2004 196
15. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans Cell 83 1995 803
16. S.A. Kliewer, J.M. Lenhard, T.M. Willson, I. Patel, D.C. Morris, and J.M. Lehmann Cell 83 1995 813
17. S.A. Kliewer, K. Umesono, D.J. Noonan, R.A. Heyman, and R.M. Evans Nature 358 1992 771
18. Docking and subsequent scoring were performed using Macromodel 8.1 software. Coordinates of PPARγ complexed with rosiglitazone were taken from the Brookhaven Protein Data Bank (PDB code 1FM6) and hydrogen atoms were added computationally at appropriate positions. The structure of a ligand bound to PPARγ was constructed by molecular mechanics (MM) energy minimization. The starting position of a ligand was determined manually: its carboxyl group was superimposed onto the TZD ring of crystallographic rosiglitazone. The conformation of the ligand in the active site was minimized by a MM calculation based upon the OPLS-AA force field with each parameter set as follows; solvent: water, method: LBFGS, Max # Iterations: 10,000, converge on: gradient, convergence threshold: 0.05
19. R.T. Gampe Jr., V.G. Montana, M.H. Lambert, A.B. Miller, R.K. Bledsoe, M.V. Milburn, S.A. Kliewer, T.M. Willson, and H.E. Xu Mol. Cell 5 2000 545
20. B.R. Henke J. Med. Chem. 47 2004 4118
21. D.C. Lagace, and M.W. Nachtigal J. Biol. Chem. 278 2004 18851
22. TM multilabelcounter (PerkinElmer, Boston, MA, U.S.A.) after staining with lipidos liquid (TOYOBO. Co., Ltd, Osaka, Japan)